ID   U2OS GFP-PEAK3
AC   CVCL_C0QT
DR   Wikidata; Q112930494
RX   PubMed=34944965;
CC   Population: Caucasian.
CC   Characteristics: Transfected with a pBABE-GFP-PEAK3 construct that contains a GFP-PEAK3 fusion (PubMed=34944965).
CC   Sequence variation: Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=FPbase; R9NL8; eGFP (Note=Enhanced GFP).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:24793; PEAK3.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0042 ! U2OS
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-04-25; Version: 8
//
RX   PubMed=34944965; DOI=10.3390/cancers13246344; PMCID=PMC8699254;
RA   Ounoughene Y., Fourgous E., Boublik Y., Saland E., Guiraud N.,
RA   Recher C., Urbach S., Fort P., Sarry J.-E., Fesquet D., Roche S.;
RT   "SHED-dependent oncogenic signaling of the PEAK3 pseudo-kinase.";
RL   Cancers (Basel) 13:6344.1-6344.18(2021).
//